Clinical Trial Update: To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating immunogenicity and safety of DTaP-IPV vaccine as a booster in healthy children aged 4-6 years.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Poliomyelitis
• Tetanus

Drugs mentioned

• DTaP-IPV vaccine

Snippet

Sponsor: Boryung Biopharma Co., Ltd. | Conditions: Diphtheria, Tetanus | Phase 3 | Status: UNKNOWN